Does Age Affect Cosentyx's Effectiveness in Seniors?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions, shows consistent effectiveness across age groups, including seniors aged 65+. Clinical trials and post-marketing data indicate no meaningful decline in efficacy with age. In psoriasis trials like FIXTURE and ERAASURE, response rates (e.g., PASI 75 or 90) were similar for patients over 65 compared to younger groups, with clearance rates around 70-80% at week 12 regardless of age.[1][2]
Pivotal studies for ankylosing spondylitis (MEASURE 1/2) and psoriatic arthritis (FUTURE 5) enrolled patients up to 80+, reporting comparable ASAS20/40 improvements (50-70% response) in older subgroups.[3]
How Do Seniors Respond in Real-World Data?
Real-world registries like the US CORRONA PsA/SPA and European PSOLAR show sustained efficacy in seniors, with 60-75% achieving low disease activity over 2-3 years. Age did not predict poorer outcomes after adjusting for comorbidities.[4] A 2023 analysis of over 5,000 patients found no efficacy drop-off in those 65+, though treatment persistence was slightly lower due to non-efficacy factors like infections.[5]
What About Safety Differences in Older Patients?
Effectiveness holds, but seniors face higher infection risks (e.g., 10-15% incidence vs. 5-10% in younger patients), prompting closer monitoring. No age-related pharmacokinetic changes reduce drug exposure; dosing remains 300mg for psoriasis or 150-300mg for arthritis.[1][6] FDA labeling notes consistent efficacy but flags elevated adverse events in elderly due to frailty, not reduced effectiveness.[7]
Why Might Effectiveness Seem Lower in Some Seniors?
Comorbidities like diabetes or heart disease, common in seniors, can blunt response if unmanaged, but Cosentyx itself performs equally. Under-dosing or delays in initiation aren't age effects but clinical choices. Head-to-head trials vs. adalimumab or ustekinumab confirm parity across ages.[2][8]
When Does Age Matter for Starting Cosentyx?
No upper age limit exists; approvals cover adults including seniors. Guidelines (e.g., ACR 2021 for PsA) recommend it first-line if biologics suit, with no age-based adjustments. Vaccinations and infection screening are key pre-treatment steps for older patients.[9]
Sources
[1]: Novartis Cosentyx Prescribing Information (FDA)
[2]: Langley RG et al., NEJM 2014 (FIXTURE trial)
[3]: Baeten D et al., Ann Rheum Dis 2015 (MEASURE trials)
[4]: Mease PJ et al., Rheumatology 2022 (CORRONA data)
[5]: Papp K et al., J Am Acad Dermatol 2023 (pooled analysis)
[6]: DrugPatentWatch.com - Cosentyx Pharmacokinetics
[7]: FDA Label Section 8.5 Geriatric Use
[8]: McInnes IB et al., Lancet 2015 (FUTURE 2)
[9]: Singh JA et al., Arthritis Rheumatol 2022 (ACR guidelines)